Physician profile
Ami Stucker
NPI 1750942637
$2,082.37
in general payments reported to CMS, 2019-2025
26 companies · $401 in 2025
The $401 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $433 · 2022: $549 · 2023: $254 · 2024: $445 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,069.54 | 2021-2025 | |
| Amgen INC. | $152.50 | 2021-2024 | Krystexxa, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.65 | 2021-2024 | Synjardy, Jardiance, Tradjenta |
| Novo Nordisk INC | $87.45 | 2021-2022 | |
| Tactile Systems Technology INC | $85.33 | 2021 | |
| Janssen Pharmaceuticals, INC | $47.90 | 2022-2024 | Spravato |
| Glaxosmithkline, LLC. | $43.45 | 2021-2024 | Shingrix |
| Sumitomo Pharma America, INC. | $40.92 | 2024 | Gemtesa |
| Boston Scientific Corporation | $38.05 | 2024 | Artisan |
| Lucid Diagnostics INC. | $37.78 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $37.26 | 2021 | |
| Pfizer INC. | $32.16 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.46 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.43 | 2022 | |
| Inogen, INC. | $22.42 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $22.38 | 2022 | |
| Organon LLC | $22.37 | 2024-2025 | Nexplanon |
| Horizon Therapeutics Plc | $20.30 | 2021 | |
| Neurocrine Biosciences, INC. | $19.28 | 2024 | Ingrezza |
| Kaleo, INC. | $18.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.58 | 2023 | |
| Amarin Pharma, INC. | $16.45 | 2021 | |
| Merck Sharp & Dohme LLC | $15.91 | 2024 | Vaxneuvance, Gardasil, Capvaxive |
| Sanofi-Aventis U.S. LLC | $14.76 | 2025 | |
| Phathom Pharmaceuticals, INC. | $13.37 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $13.06 | 2023 | Evusheld |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Stucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.